Studies on Hageman Factor, Plasmin and Kallikrein
スポンサーリンク
概要
- 論文の詳細を見る
It is well known that plasma kinins which appear during inflammation or antigen-antibody reactions are formed by action of proteases such as plasmin and kallikrein. These plasmin and kallikrein originate from plasminogen and kallikreinogen, inactive precursors found in blood. It has been suggested that these are activated by Hageman factor in blood, by which activation plasminogen and kallikreinogen are successively converted into plasmin and kallikrein, resulting in formation of these latters form kinins from kininogen, respectively. However, there is no evidence indicating existence of such activation systems except kinin formation by kallikrein. Although many investigators have reported kinin formation by plasmin, no direct evidence have been demonstrated. We reported last year at this symposium that plasmin could convert directly kininogen into kinins. In 1964, Vogt suggested that plasmin might form kinins indirectly, through the mediation of its formation of kallikrein from kallikreinogen.<BR>At this symposium, we tried to confirm his hypothesis and also examined whether or not the activated Hageman factor could convert plasminogen and kallikreinogen into plasmin and kallikrein, respectively. It was demonstrated that human plasmin and kallikrein was successfully separated by column chromatography on DEAE Sephadex A-50. Then, conversion of kallikreinogen into kallikrein by plasmin was examined by means of this column chromatography. However, we could not obtain any evidence showing the existence of such conversion. We also tried to confirm the above result by using purified kallikreinogen. The purification was carried out in accordance with the following procedures. Euglobulin fraction separated from human plasma was suspended in 0.03M EDTA solution, stirred overnight at 4°C and centrifuged. The resulting supernatant contained kallikreinogen and the precipitate included most of plasminogen. Then, plasmin was made to act on the kallikreinogen purified by these procedures and conversion of kallikreinogen into kallikrein by plasmin was examined. No evidence, however, was obtained indicating that plasmin converted kallikreinogen into kallikrein.<BR>Activated Hageman factor was purified by the Schoenmakers' method to investigate whether or not the activated Hageman factor can convert plasminogen and kallikreinogen into plasmin and kallikrein, respectively. Activity was measured by means of caseinolysis in case of activation of plasminogen and of TAMe activity in case of activation of kallikreinogen. It was clarified that the Hageman factor could convert kallikreinogen into kallikrein, but not plasminogen into plasmin.<BR>Finally, we succeeded in synthesis of a kallikrein inhibitor, that is, δ-guanidino valeric acid hexyl ester. This substance inhibited plasmin as well as kallikrein.
- Japan Society of Clinical Chemistryの論文
著者
-
渡辺 英生
徳島大学医学部第1外科学教室
-
藤井 節郎
徳島大学医学部酵素研究施設
-
村松 睦
徳島大学医学部酵素生理
-
安倍 文計
徳島大学医学部第1外科
-
藤井 節郎
徳島大学医学部酵素研究施設酵素生理
-
安倍 文計
徳島大学医学部酵素研究施設酵素生理
-
渡辺 英生
徳島大学医学部第1外科
関連論文
- Zollinger-Ellison 症候群 : 胃全摘後の malignant gastrinoma の消長ならびに血清ガストリン値について
- 制癌剤1-(2-Tetrahydrofuryl)-5-fluorouracil(FT一207), の生体内運命(第3報)直腸内投与による吸収, 体内分布, 排泄および代謝
- 4. C1-inhibitorの精製および抗原抗体反応における役割(第9回補体シンポジウム)
- 11.C1エステラーゼおよびプロC1sの精製(第8回補体シンポジウム)
- 1. C1の研究(第9回補体シンポジウム)
- 医学におけるリパーゼとその意義
- 胃•十二指腸疾患と血清ガストリン値 : 空腹時血清ガストリン値について
- 鎖肛を伴わない直腸腟前庭瘻の考察 : 類似病態と新病型分類の提唱
- Studies on Kallikrein and Blood Pressure
- Regulation of Lipid Metabolism and Modified Enzyme
- Role of Enzymes in Inflammation
- Mechanism of ACTH Action in Corticosteroidogenesis of Rat Adrenal
- Regulatory Mechanism of Fatty Acid Metabolism
- Studies on Leucine Aminopeptidase
- Biological Role of Cl-esterase
- Studies on Hageman Factor, Plasmin and Kallikrein
- Mechanism of Adrenaline Induced Lipolysis and CyclicAMP
- Study on Clearing Factor Lipase
- Mechanism of ACTH Action
- Purification of Proteolytic Enzymes in Plasma and Other Enzymes by Affinity Chromatography
- New Methods for Determination of Various Plasma Deaminases and their Clinical Applications